US Edition
Study Claims Ozempic May Also Help Reduce Dementia Risk
- A study published on June 24, 2025, examined the association between semaglutide use and dementia risk among U.S. adults with type 2 diabetes, finding that those taking semaglutide had a lower likelihood of developing dementia compared to users of other antidiabetic treatments.
- A team from Case Western Reserve University School of Medicine examined electronic health records spanning three years for nearly 1.7 million patients to evaluate semaglutide in comparison with seven other antidiabetic medications.
- The observational study found that patients taking semaglutide had a 46% lower chance of developing dementia compared to those on insulin and a 33% lower chance compared to metformin, with the most pronounced benefits observed in individuals under 65, women, and those with obesity.
- Professor Rong Xu highlighted that their research found patients using semaglutide experienced a notably reduced chance of developing Alzheimer’s disease and related dementias compared to those treated with other diabetes medications, while emphasizing that definitive causal relationships need to be confirmed through randomized clinical trials.
- Novo Nordisk began randomized clinical trials of semaglutide in early Alzheimer's patients in 2021, with results expected in 2025 to clarify the drug's potential for dementia prevention.
44 Articles
44 Articles
Could Ozempic Lower Your Risk of Dementia?
Originally designed to treat type 2 diabetes, GLP-1 medications like Ozempic and Wegovy quickly made it into the hands of every now-formerly hefty person in your life. A new study suggests that these drugs, specifically their active ingredient semaglutide, might be shielding your brain from dementia in addition to melting fat. Researchers at Case Western Reserve University, led by Rong Xu, just published a study in the Journal of Alzheimer’s Dis…
Taking Semaglutide Could Cut Dementia Risk Nearly In Half, Case Western Study Shows
Beyond helping diabetes patients lose weight and control blood sugar, semaglutide appears to cut dementia risk by nearly half, according to a large new study. The post Taking Semaglutide Could Cut Dementia Risk Nearly In Half, Case Western Study Shows appeared first on Study Finds.
Study Links Some Weight Loss Drugs to Lower Risk of Dementia
A new study published in the Journal of Alzheimer’s Disease has found that the active ingredient in popular drugs like Ozempic and Wegovy may lower the risk of developing dementia. NBC News medical contributor Dr. Natalie Azar stops by TODAY to break down the key takeaways from the study.
1. 7 million patients reveal stunning link between semaglutide and lower dementia risk
A blockbuster diabetes and weight-loss drug might be doing more than controlling blood sugar—it could also be protecting the brain. Researchers at Case Western Reserve University found that people with type 2 diabetes who took semaglutide (the active ingredient in Ozempic and Wegovy) had a significantly lower risk of developing dementia. The benefit was especially strong in women and older adults.
Coverage Details
Bias Distribution
- 50% of the sources are Center
To view factuality data please Upgrade to Premium
